{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jarvis JN"],"funding":["Styrelsen för Internationellt Utvecklingssamarbete","European and Developing Countries Clinical Trials Partnership","FIC NIH HHS","Department for International Development, UK Government","Department for International Development","Medical Research Council","National Institute for Health Research (NIHR)","NINDS NIH HHS","Wellcome Trust"],"pagination":["1109-1120"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7612678"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["386(12)"],"pubmed_abstract":["<h4>Background</h4>Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa. Whether a treatment regimen that includes a single high dose of liposomal amphotericin B would be efficacious is not known.<h4>Methods</h4>In this phase 3 randomized, controlled, noninferiority trial conducted in five African countries, we assigned HIV-positive adults with cryptococcal meningitis in a 1:1 ratio to receive either a single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day) or the current World Health Organization-recommended treatment, which includes amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytos"],"journal":["The New England journal of medicine"],"pubmed_title":["Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis."],"pmcid":["PMC7612678"],"funding_grant_id":["203135","214321","206007","K01 TW010268","RP-2017-08-ST2-012","214321/Z/18/Z","R01 NS086312","TRIA2015-1092","MC_PC_MR/P006922/1","MR/P006922/1","203135/Z/16/Z","098316"],"pubmed_authors":["Kumwenda M","Kugonza F","Masina N","Kukacha C","Jarvis JN","Shah R","Morar T","Chitulo G","Williams D","Schutz C","Ssemusu M","Tugume L","Mnguni T","April S","Mwarumba T","Kiiza D","Tegha G","Chimang'anga W","Zambasa A","Ndyetukira J","Rutakingirwa MK","Hafeez S","Ndalama M","Rulaganyang I","Sadiq A","Muthoga C","Naude J","Lipenga B","Kanyama C","Mmipi R","Kufa P","Mudzingwa S","Mpoza E","Maya C","Lawrence DS","Molloy SF","Ponatshego P","Mphande C","Youssouf N","Zinyandu T","Alice A","Maughan D","Boloko L","Moyo M","Rwomushana I","Mhango W","Kyepa H","Mawoko N","Lalloo DG","Goodall J","Chimphambano T","Lechiile K","Stott K","Lortholary O","Davids L","Muzoora C","Ngoma D","Kagimu E","Okirwoth M","Sturny-Leclere A","Chome N","Sebesho L","Goliath R","Nicholas S","Shey M","Sayed S","Swanepoel L","Boyer-Chammard T","Rodgers A","Kadzilimbile A","Jjunju S","Comins K","Inyakuwa C","Bookholane H","Akampurira A","Singh A","Oliphant I","Alanio A","Siamisang K","Dromer F","Msumba L","Mwesigye J","Mutata C","Kumwenda E","Gakuru J","Cresswell F","Singini A","Kazembe M","Rukundo J","Atwine L","Kachitosi T","Gondwe E","Wang D","Kisembo J","Zambezi J","Kamanga B","Loyse A","Munthali T","Ahimbisibwe C","Tadeo K","Bekiswa A","Emily N","Chawinga C","Moosa S","Boyd K","Hosseinipour MC","Milburn J","Dziwani E","Hoffman R","Chasweka M","Chen T","Griffin P","Crede T","Hlungulu S","Mtisi T","Tlhako N","Namujju O","Ssebambulidde K","Rhein J","Kateta S","Mzinganjira H","Nsangi L","Meya DB","Ambition Study Group","Buzaare P","Muyise R","Luggya T","Ndaferankhande J","Hope W","Kossam E","Meintjes G","Tsholo K","Moyo C","Kasibante J","Gwin M","Mbangiwa T","Leeme T","Mwandumba HC","Mosepele M","Lule A","Kariisa S","Niwamanya S","Jaffar S","Stambuli A","Boulware DR","Stead G","Chiwoko L","van Widenfelt E","Harrison TS","Tukundane A","Gondo S","Nuwagira E","Chikaonda T","Musubire A","Kwizera R","Seatla K","Mpalali M","Simwinga L","Hlupeni A","Ndhlovu CE","Laker E","Collins M","Makaha E","Banda T"],"additional_accession":[]},"is_claimable":false,"name":"Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.","description":"<h4>Background</h4>Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa. Whether a treatment regimen that includes a single high dose of liposomal amphotericin B would be efficacious is not known.<h4>Methods</h4>In this phase 3 randomized, controlled, noninferiority trial conducted in five African countries, we assigned HIV-positive adults with cryptococcal meningitis in a 1:1 ratio to receive either a single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day) or the current World Health Organization-recommended treatment, which includes amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytos","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T07:44:23.977Z","creation":"2025-04-04T07:44:23.977Z"},"accession":"S-EPMC7612678","cross_references":{"pubmed":["35320642"],"doi":["10.1056/NEJMoa2111904"]}}